Intraperitoneal Dexmedetomidine Versus Magnesium as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy
Intraperitoneal Instillation of Dexmedetomidine Versus Magnesium Sulphate as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy
Alexandria University
80 participants
May 3, 2026
INTERVENTIONAL
Conditions
Summary
Although both dexmedetomidine and magnesium sulphate have been individually evaluated as adjuvants to local anesthetics, direct comparisons between the two agents in intraperitoneal instillation during laparoscopic cholecystectomy remain limited. Understanding their relative efficacy and safety could provide valuable guidance for optimizing perioperative analgesia in these patients.
Eligibility
Inclusion Criteria3
- Patients aged 18-60 years
- ASA physical status I-II
- scheduled for elective laparoscopic cholecystectomy under general anesthesia.
Exclusion Criteria7
- Known hypersensitivity to study drugs
- history of cardiac arrhythmias or conduction abnormalities
- severe hepatic/renal impairment
- chronic opioid or analgesic use
- pregnancy
- conversion to open surgery
- drain insertion.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
20 ml bupivacaine + 1 µg/kg dexmedetomidine . The total volume will be adjusted to 50 mL with saline.
20 ml bupivacaine + 50 mg/kg magnesium sulphate . The total volume will be adjusted to 50 mL with saline.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07693621